{"filing":{"accession_number":"0001104659-26-086068","cik":"0001082554","ticker":"UTHR","company_name":"UNITED THERAPEUTICS Corp","form":"8-K","filing_date":"2026-07-23","report_date":null,"primary_document":"tm2620809d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1082554/000110465926086068/tm2620809d1_8k.htm"},"events":[{"id":19798,"run_id":17817,"accession_number":"0001104659-26-086068","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Victor Dzau, M.D., was appointed to the Board of Directors of United Therapeutics on July 22, 2026, increasing the Board size to 13 members. As part of his appointment, Dr. Dzau received initial equity compensation consisting of 380 RSUs and 1,190 stock options, plus pro-rata awards.","company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":[{"id":18989,"accession_number":"0001104659-26-086068","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Victor Dzau, M.D., to the Board of Directors on July 22, 2026, with the Board increasing its size to 13 members. While the disclosure also includes equity compensation details (380 RSUs, 1,190 stock options as initial grant, plus pro-rata awards), the principal action is the appointment of a director with significant healthcare leadership credentials. This is a material governance event affecting board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T11:03:42.540809+00:00","company_name":"","ticker":null,"filing_date":""},{"id":18990,"accession_number":"0001104659-26-086068","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Victor Dzau, M.D., to United Therapeutics' Board of Directors on July 22, 2026. The press release emphasizes his distinguished career as a physician-scientist, his recent tenure as President of the National Academy of Medicine, and his expertise in healthcare leadership and medical research. This is a material governance event affecting board composition at a public company, and the principal disclosed action is a person taking a role on the board.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T11:03:42.540809+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18989,"accession_number":"0001104659-26-086068","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Victor Dzau, M.D., to the Board of Directors on July 22, 2026, with the Board increasing its size to 13 members. While the disclosure also includes equity compensation details (380 RSUs, 1,190 stock options as initial grant, plus pro-rata awards), the principal action is the appointment of a director with significant healthcare leadership credentials. This is a material governance event affecting board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T11:03:42.540809+00:00","company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","filing_date":"2026-07-23"},{"id":18990,"accession_number":"0001104659-26-086068","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Victor Dzau, M.D., to United Therapeutics' Board of Directors on July 22, 2026. The press release emphasizes his distinguished career as a physician-scientist, his recent tenure as President of the National Academy of Medicine, and his expertise in healthcare leadership and medical research. This is a material governance event affecting board composition at a public company, and the principal disclosed action is a person taking a role on the board.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T11:03:42.540809+00:00","company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","filing_date":"2026-07-23"}]}